These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26693692)
1. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692 [TBL] [Abstract][Full Text] [Related]
2. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Adhikary G; Grun D; Balasubramanian S; Kerr C; Huang JM; Eckert RL Carcinogenesis; 2015 Jul; 36(7):800-10. PubMed ID: 25969142 [TBL] [Abstract][Full Text] [Related]
3. Verification of EZH2 as a druggable target in metastatic uveal melanoma. Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003 [TBL] [Abstract][Full Text] [Related]
4. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782 [No Abstract] [Full Text] [Related]
5. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia. Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525 [No Abstract] [Full Text] [Related]
6. Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype. Ezeka G; Adhikary G; Kandasamy S; Friedberg JS; Eckert RL Mol Carcinog; 2021 Jul; 60(7):429-439. PubMed ID: 33872411 [TBL] [Abstract][Full Text] [Related]
7. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF. Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303 [TBL] [Abstract][Full Text] [Related]
10. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976 [TBL] [Abstract][Full Text] [Related]
11. Sulforaphane regulates the proliferation of leukemia stem-like cells via Sonic Hedgehog signaling pathway. Wang F; Huang X; Sun Y; Li Z; Sun R; Zhao T; Wang M; Yan C; Liu P Eur J Pharmacol; 2022 Mar; 919():174824. PubMed ID: 35157913 [TBL] [Abstract][Full Text] [Related]
12. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. Rodova M; Fu J; Watkins DN; Srivastava RK; Shankar S PLoS One; 2012; 7(9):e46083. PubMed ID: 23029396 [TBL] [Abstract][Full Text] [Related]
13. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653 [TBL] [Abstract][Full Text] [Related]
14. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. Yen SY; Chuang HM; Huang MH; Lin SZ; Chiou TW; Harn HJ Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208648 [TBL] [Abstract][Full Text] [Related]
15. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Wen Y; Cai J; Hou Y; Huang Z; Wang Z Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635 [TBL] [Abstract][Full Text] [Related]
16. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929 [TBL] [Abstract][Full Text] [Related]
17. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2. Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375 [TBL] [Abstract][Full Text] [Related]
18. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas. Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor. Kampilafkos P; Melachrinou M; Kefalopoulou Z; Lakoumentas J; Sotiropoulou-Bonikou G Am J Dermatopathol; 2015 Feb; 37(2):138-44. PubMed ID: 25614949 [TBL] [Abstract][Full Text] [Related]
20. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Zeng D; Liu M; Pan J Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]